<DOC>
	<DOC>NCT00999336</DOC>
	<brief_summary>The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.</brief_summary>
	<brief_title>A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Able to understand and sign the written informed consent. Subjects should have either normal renal function or have stable renal disease Subjects require dialysis Evidence of active bleeding or bleeding disorder Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Betrixaban</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>Healthy</keyword>
	<keyword>Kidney dysfunction</keyword>
</DOC>